History of Pancreatitis Prior to initiating retatrutide, clinicians should inquire about previous pancreatitis or current pancreatic disease
In a new study, patients taking semaglutide experienced as much as a 52% reduction in kidney damage
Across the SURPASS (type 2 diabetes) and SURMOUNT (body composition management) trial programmes, nausea was reported in approximately 2024% of participants on lower doses and up to 2430% on higher doses
Participants receiving semaglutide 2.4 mg weekly achieved an average body weight reduction of approximately 14.9%, compared to 2.4% in the placebo group
The understanding so far has been that GLP-1 analogues work by mimicking the action of a similarly shaped molecule called glucagon-like peptide, which is naturally released by the intestines soon after eating food
10.6% Weight Loss (0.5mg)* 24 Week Phase 2 Trial 1x Daily Oral Dose TBD FDA Status Pending Coming Soon A novel oral weight loss medication that works through brain neurotransmitter pathways rather than gut hormonesoffering an alternative approach for patients who prefer pills over injections
